ALFA Finder| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 197.9 | 143.8 | 216.5 |
| Other income | 3.0 | 2.7 | 8.5 |
| Total income | 201.0 | 146.5 | 225.1 |
| Profit before exceptional items & tax | 47.3 | 26.2 | 41.8 |
| Exceptional items | -1.0 | 0.0 | -17.0 |
| Profit before tax | 46.3 | 26.2 | 22.2 |
| Net profit | 34.4 | 21.3 | 8.8 |
| Operating margin | 23.0% | 17.9% | 9.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +290.90% |
|---|---|
| Net profit, quarter on quarter | +61.50% |
| Revenue, year on year | -8.60% |
NSE results filing, NSE: QLINE. Figures extracted from the filing.
Q-Line Biotech Ltd: key numbers
- Share price
- ₹552.10
- Market cap
- ₹1,288 Cr
- Revenue (annual)
- ₹341.7 Cr
- Net profit (annual)
- ₹55.72 Cr
- P/E (TTM)
- 23.1×Sector 54.5×
- Promoter holding
- 67.51%
- FII holding
- 0.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Q-Line Biotech Ltd
All →Q-Line Biotech Board Meeting Date
Q-Line Biotech clarified a clerical error: its board meeting time is 4:15 PM, not 3:00 PM. The November 12, 2026 meeting will consider half-yearly financial results.
Q-Line Biotech Annual General Meeting
Q-Line Biotech Limited held its 16th Annual General Meeting on September 30, 2026. The meeting transacted ordinary and special business, including financial statement adoption and director re-appointments.
Q-Line Biotech Annual General Meeting
Q-Line Biotech has sent a letter to shareholders with bounced emails, providing links to the Annual Report and 16th AGM Notice, scheduled for September 30, 2026.
Q-Line Biotech Annual Report
Q-Line Biotech Limited has submitted its Annual Report for the financial year 2025-26. The full document is accessible via the provided company website link.
Q-Line Biotech Board Meeting Outcome
Q-Line Biotech approved the Board's Report, notice for the 16th AGM, and re-appointment of two Whole Time Directors and the Cost Auditor.
Q-Line Biotech Other Announcement
Q-Line Biotech Limited has re-appointed M/s. P S P & Associates as Cost Auditors for a 12-month term.
- Execution
- 12 months